• Report Description
  • Table Of Content
  • Request Methodology

KD Market Insights added a title on “Hepatocellular Carcinoma Drugs Market – 2019-2024” to its collection of industry research reports that offers extensive and highly detailed current and future market trends in the global and regional/market. The report includes market size, Y-O-Y growth analysis and structure of the overall industry based on a unique combination of industry research, fieldwork, market sizing analysis, and our in-house expertise.

The market research report demonstrates market dynamics which includes growth drivers, restraining factors and opportunities and trends spearheading current Drug Class and future status of this market. Our general approach is to target several individuals with specific questions that we believed would satisfy our research objective. Further, to speed up the data collection process, we employed an online survey, delivered via email. The research team analyzed the results to identify potential opportunities and risks for the market.

In addition, the report offers recent industry activities and value chain analysis for the Hepatocellular Carcinoma Drugs Market. Moreover, Porter’s Five Forces analysis demonstrates the five forces which include buyers bargaining power, suppliers bargaining power, the threat of new entrants, the threat of substitutes, and degree of competition in Hepatocellular Carcinoma Drugs Market. Along with figures and tables, a market attractiveness and BPS analysis has been provided for every segment in the report.

Global Hepatocellular Carcinoma Drugs Market Size & Forecast:

Global Hepatocellular Carcinoma Drugs market witnessed a market value of USD XX Million in 2019 and is estimated to reach USD XX million in 2024, registering a compound annual growth rate (CAGR) of XX% between 2019 and 2024. The report analyses the market by geographies i.e. North America, Europe, Asia Pacific, Latin America & Middle East & Africa. Further, the geographies are fragmented into the country and regional groupings:

- North America (U.S. & Canada)
- Europe (Germany, United Kingdom, France, Italy, Spain, Russia and Rest of Europe)
- Asia Pacific (China, India, Japan, South Korea, Indonesia, Taiwan, Australia, New Zealand and Rest of Asia Pacific)
- Latin America (Brazil, Mexico, Argentina and Rest of Latin America)
- Middle East & Africa (GCC, North Africa, South Africa and Rest of Middle East & Africa)

Global Hepatocellular Carcinoma Drugs Market Segmentation:

The research offers a comprehensive analysis of global Hepatocellular Carcinoma Drugs market with respect to following sub-markets:

Based on Drug Class:
- PD-1/PD-L1 Inhibitors
- - - Nivolumab (Opdivo)
- Tyrosine Kinase Inhibitors
- - - Sorafenib (Nexavar)
- - - Regorafenib (Stivarga)

Based on End-user:
- Hospital
- Clinics
- Cancer Rehabilitation Centers
- Ambulatory Surgical Centers

Global Hepatocellular Carcinoma Drugs Market: Competitive Landscape

The report also highlights the competitive landscape of the global Hepatocellular Carcinoma Drugs market, market share and positioning of all the major players in the industry. The competitive landscape analysis provides detailed strategic analysis of the company’s business and performance such as company overview, financial information, revenue breakup by segment and by geography, SWOT Analysis, key facts, business strategy, key product offerings, marketing and distribution strategies, new product development, recent news (acquisition, expansion, Drug Class development, research & development and other market activities).

The report includes profiles of leading companies in the global Hepatocellular Carcinoma Drugs market.

Some of the key players profiled include:

- Novartis Pharmaceuticals
- Bayer AG
- Merck & Co., Inc.
- Bristol-Myers Squibb Company
- AbbVie Inc.
- Johnson & Johnson
- Celgen Corporation
- Amgen Inc.
- Teva Pharmaceutical Industries Ltd.
- Pfizer Inc.
- Takeda Pharmaceutical Co. Ltd.
- Other Major & Niche Key Players

Timeline Considered for Analysis:

- 2015 to 2017 – Historical Year
- 2018 – Base Year
- 2019 – Estimated Year
- 2019 to 2024 – Forecasted Year

Customization: We also offers customization’s in the industry report as per the company’s specific needs.

Key Questions Answered in the Global Hepatocellular Carcinoma Drugs Industry Report:

- What is the overall market size in 2018? What will be the market growth during the forecast period i.e. 2019-2024?
- Which region would have high demand for product in the upcoming years?
- What are the factors driving the growth of the market?
- Which sub-market will make the most significant contribution to the market?
- What are the market opportunities for existing and entry-level players?
- What are various long-term and short-term strategies adopted by the market players?

1. Preface

1.1. Research Methodology
1.1.1. Industry Research
1.1.2. Research Process and Design
1.1.2.1. Secondary Research
1.1.2.2. Key Sources and Use of Primary Research
1.1.2.3. Market Size Estimation and Forecast
1.1.2.4. Research Report
1.2. Geographic Scope
1.3. Years Considered
1.4. Key Deliverables of the Study
1.5. Assumptions and Limitations for Market Estimation and Forecasting

2. Executive Summary

2.1. Market Snapshot
2.2. Market Overview
2.3. CXO Perspective
2.4. Top Global Hepatocellular Carcinoma Drugs Market Trends for 2019

3. Porter’s Five Force Analysis

3.1. Threat of Substitutes
3.2. Bargaining Power of Buyers
3.3. Bargaining Power of Suppliers
3.4. Threat of New Entrants
3.5. Degree of Competition

4. Manufacturing Cost Structure Analysis

4.1. Raw Material and Suppliers
4.2. Industry Chain Structure of Hepatocellular Carcinoma Drugs
4.3. Manufacturing Process Analysis of Hepatocellular Carcinoma Drugs
4.4. Manufacturing Cost Structure Analysis of Hepatocellular Carcinoma Drugs

5. Manufacturing Plants Analysis of Hepatocellular Carcinoma Drugs

5.1. Capacity and Production
5.2. Global Hepatocellular Carcinoma Drugs Manufacturing Plants Distribution
5.3. Recent Development and Expansion Plans

6. Competitive Landscape

6.1. Global Hepatocellular Carcinoma Drugs Market 2018
6.2. Global Hepatocellular Carcinoma Drugs Market Value Share, By Company 2018
6.3. Global Hepatocellular Carcinoma Drugs Market Volume Share, By Company 2018

7. Market Dynamics

7.1. Growth Drivers & Barriers in Hepatocellular Carcinoma Drugs Market
7.1.1. North America
7.1.2. Europe
7.1.3. Asia Pacific
7.1.4. Rest of World
7.2. Opportunities in Hepatocellular Carcinoma Drugs Market

8. Global Hepatocellular Carcinoma Drugs Market

8.1. Introduction
8.2. Key Trends & Growth Drivers
8.3. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
8.4. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024

9. Global Hepatocellular Carcinoma Drugs Market Segmentation Analysis, By Drug Class

9.1. Introduction
9.2. Strategic Insights
9.2.1. BPS Analysis, By Drug Class
9.2.2. Market Attractiveness, By Drug Class
9.2.3. PD-1/PD-L1 Inhibitors
9.2.3.1. Nivolumab (Opdivo)
9.2.3.1.1. Key Trends & Growth Drivers
9.2.3.1.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
9.2.3.1.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
9.2.4. Tyrosine Kinase Inhibitors
9.2.4.1. Sorafenib (Nexavar)
9.2.4.1.1. Key Trends & Growth Drivers
9.2.4.1.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
9.2.4.1.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
9.2.4.2. Regorafenib (Stivarga)
9.2.4.2.1. Key Trends & Growth Drivers
9.2.4.2.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
9.2.4.2.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024

10. Global Hepatocellular Carcinoma Drugs Market Segmentation Analysis, By End-user

10.1. Introduction
10.2. Strategic Insights
10.2.1. BPS Analysis, By End-user
10.2.2. Market Attractiveness, By End-user
10.3. Hospital
10.3.1. Key Trends & Growth Drivers
10.3.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
10.3.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
10.4. Clinics
10.4.1. Key Trends & Growth Drivers
10.4.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
10.4.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
10.5. Cancer Rehabilitation Centers
10.5.1. Key Trends & Growth Drivers
10.5.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
10.5.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
10.6. Ambulatory Surgical Centers
10.6.1. Key Trends & Growth Drivers
10.6.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
10.6.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024

11. Geographical Analysis

11.1. Introduction
11.2. North America Hepatocellular Carcinoma Drugs Market
11.2.1. Key Trends & Growth Drivers
11.2.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.2.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.2.4. By Drug Class
11.2.4.1. Introduction
11.2.4.2. Strategic Insights
11.2.4.2.1. BPS Analysis, By Drug Class
11.2.4.2.2. Market Attractiveness, By Drug Class
11.2.4.3. PD-1/PD-L1 Inhibitors
11.2.4.3.1. Nivolumab (Opdivo)
11.2.4.3.1.1. Key Trends & Growth Drivers
11.2.4.3.1.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.2.4.3.1.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.2.4.4. Tyrosine Kinase Inhibitors
11.2.4.4.1. Sorafenib (Nexavar)
11.2.4.4.1.1. Key Trends & Growth Drivers
11.2.4.4.1.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.2.4.4.1.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.2.4.4.2. Regorafenib (Stivarga)
11.2.4.4.2.1. Key Trends & Growth Drivers
11.2.4.4.2.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.2.4.4.2.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.2.5. By End-user
11.2.5.1. Introduction
11.2.5.2. Strategic Insights
11.2.5.2.1. BPS Analysis, By End-user
11.2.5.2.2. Market Attractiveness, By End-user
11.2.5.3. Hospitals
11.2.5.3.1. Key Trends & Growth Drivers
11.2.5.3.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.2.5.3.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.2.5.4. Oncology Centers
11.2.5.4.1. Key Trends & Growth Drivers
11.2.5.4.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.2.5.4.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.2.5.5. Others
11.2.5.5.1. Key Trends & Growth Drivers
11.2.5.5.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.2.5.5.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.2.6. By Country
11.2.6.1. Introduction
11.2.6.2. Strategic Insights
11.2.6.2.1. BPS Analysis, By Country
11.2.6.2.2. Market Attractiveness, By Country
11.2.6.3. U.S. Hepatocellular Carcinoma Drugs Market
11.2.6.3.1. Key Trends & Growth Drivers
11.2.6.3.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.2.6.3.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.2.6.4. Canada Hepatocellular Carcinoma Drugs Market
11.2.6.4.1. Key Trends & Growth Drivers
11.2.6.4.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.2.6.4.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024

11.3. Europe Hepatocellular Carcinoma Drugs Market

11.3.1. Key Trends & Growth Drivers
11.3.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.3.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.3.4. By Drug Class
11.3.4.1. Introduction
11.3.4.2. Strategic Insights
11.3.4.2.1. BPS Analysis, By Drug Class
11.3.4.2.2. Market Attractiveness, By Drug Class
11.3.4.3. PD-1/PD-L1 Inhibitors
11.3.4.3.1. Nivolumab (Opdivo)
11.3.4.3.1.1. Key Trends & Growth Drivers
11.3.4.3.1.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.3.4.3.1.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.3.4.4. Tyrosine Kinase Inhibitors
11.3.4.4.1. Sorafenib (Nexavar)
11.3.4.4.1.1. Key Trends & Growth Drivers
11.3.4.4.1.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.3.4.4.1.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.3.4.4.2. Regorafenib (Stivarga)
11.3.4.4.2.1. Key Trends & Growth Drivers
11.3.4.4.2.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.3.4.4.2.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.3.5. By End-user
11.3.5.1. Introduction
11.3.5.2. Strategic Insights
11.3.5.2.1. BPS Analysis, By End-user
11.3.5.2.2. Market Attractiveness, By End-user
11.3.5.3. Hospitals
11.3.5.3.1. Key Trends & Growth Drivers
11.3.5.3.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.3.5.3.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.3.5.4. Oncology Centers
11.3.5.4.1. Key Trends & Growth Drivers
11.3.5.4.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.3.5.4.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.3.5.5. Others
11.3.5.5.1. Key Trends & Growth Drivers
11.3.5.5.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.3.5.5.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.3.6. By Country
11.3.6.1. Introduction
11.3.6.2. Strategic Insights
11.3.6.2.1. BPS Analysis, By Country
11.3.6.2.2. Market Attractiveness, By Country
11.3.6.3. Germany Hepatocellular Carcinoma Drugs Market
11.3.6.3.1. Key Trends & Growth Drivers
11.3.6.3.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.3.6.3.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.3.6.4. United Kingdom Hepatocellular Carcinoma Drugs Market
11.3.6.4.1. Key Trends & Growth Drivers
11.3.6.4.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.3.6.4.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.3.6.5. France Hepatocellular Carcinoma Drugs Market
11.3.6.5.1. Key Trends & Growth Drivers
11.3.6.5.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.3.6.5.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.3.6.6. Italy Hepatocellular Carcinoma Drugs Market
11.3.6.6.1. Key Trends & Growth Drivers
11.3.6.6.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.3.6.6.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.3.6.7. Spain Hepatocellular Carcinoma Drugs Market
11.3.6.7.1. Key Trends & Growth Drivers
11.3.6.7.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.3.6.7.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.3.6.8. Russia Hepatocellular Carcinoma Drugs Market
11.3.6.8.1. Key Trends & Growth Drivers
11.3.6.8.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.3.6.8.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.3.6.9. Rest of Europe Hepatocellular Carcinoma Drugs Market
11.3.6.9.1. Key Trends & Growth Drivers
11.3.6.9.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.3.6.9.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024

11.4. Asia Pacific Hepatocellular Carcinoma Drugs Market

11.4.1. Key Trends & Growth Drivers
11.4.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.4.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.4.4. By Drug Class
11.4.4.1. Introduction
11.4.4.2. Strategic Insights
11.4.4.2.1. BPS Analysis, By Drug Class
11.4.4.2.2. Market Attractiveness, By Drug Class
11.4.4.3. PD-1/PD-L1 Inhibitors
11.4.4.3.1. Nivolumab (Opdivo)
11.4.4.3.1.1. Key Trends & Growth Drivers
11.4.4.3.1.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.4.4.3.1.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.4.4.4. Tyrosine Kinase Inhibitors
11.4.4.4.1. Sorafenib (Nexavar)
11.4.4.4.1.1. Key Trends & Growth Drivers
11.4.4.4.1.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.4.4.4.1.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.4.4.4.2. Regorafenib (Stivarga)
11.4.4.4.2.1. Key Trends & Growth Drivers
11.4.4.4.2.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.4.4.4.2.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.4.5. By End-user
11.4.5.1. Introduction
11.4.5.2. Strategic Insights
11.4.5.2.1. BPS Analysis, By End-user
11.4.5.2.2. Market Attractiveness, By End-user
11.4.5.3. Hospitals
11.4.5.3.1. Key Trends & Growth Drivers
11.4.5.3.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.4.5.3.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.4.5.4. Oncology Centers
11.4.5.4.1. Key Trends & Growth Drivers
11.4.5.4.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.4.5.4.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.4.5.5. Others
11.4.5.5.1. Key Trends & Growth Drivers
11.4.5.5.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.4.5.5.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.4.6. By Country
11.4.6.1. Introduction
11.4.6.2. Strategic Insights
11.4.6.2.1. BPS Analysis, By Country
11.4.6.2.2. Market Attractiveness, By Country
11.4.6.3. China Hepatocellular Carcinoma Drugs Market
11.4.6.3.1. Key Trends & Growth Drivers
11.4.6.3.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.4.6.3.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.4.6.4. India Hepatocellular Carcinoma Drugs Market
11.4.6.4.1. Key Trends & Growth Drivers
11.4.6.4.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.4.6.4.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.4.6.5. Japan Hepatocellular Carcinoma Drugs Market
11.4.6.5.1. Key Trends & Growth Drivers
11.4.6.5.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.4.6.5.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.4.6.6. South Korea Hepatocellular Carcinoma Drugs Market
11.4.6.6.1. Key Trends & Growth Drivers
11.4.6.6.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.4.6.6.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.4.6.7. Indonesia Hepatocellular Carcinoma Drugs Market
11.4.6.7.1. Key Trends & Growth Drivers
11.4.6.7.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.4.6.7.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.4.6.8. Taiwan Hepatocellular Carcinoma Drugs Market
11.4.6.8.1. Key Trends & Growth Drivers
11.4.6.8.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.4.6.8.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.4.6.9. Australia Hepatocellular Carcinoma Drugs Market
11.4.6.9.1. Key Trends & Growth Drivers
11.4.6.9.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.4.6.9.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.4.6.10. New Zealand Hepatocellular Carcinoma Drugs Market
11.4.6.10.1. Key Trends & Growth Drivers
11.4.6.10.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.4.6.10.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.4.6.11. Rest of Asia Pacific Hepatocellular Carcinoma Drugs Market
11.4.6.11.1. Key Trends & Growth Drivers
11.4.6.11.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.4.6.11.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024

11.5. Latin America Hepatocellular Carcinoma Drugs Market

11.5.1. Key Trends & Growth Drivers
11.5.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.5.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.5.4. By Drug Class
11.5.4.1. Introduction
11.5.4.2. Strategic Insights
11.5.4.2.1. BPS Analysis, By Drug Class
11.5.4.2.2. Market Attractiveness, By Drug Class
11.5.4.3. PD-1/PD-L1 Inhibitors
11.5.4.3.1. Nivolumab (Opdivo)
11.5.4.3.1.1. Key Trends & Growth Drivers
11.5.4.3.1.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.5.4.3.1.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.5.4.4. Tyrosine Kinase Inhibitors
11.5.4.4.1. Sorafenib (Nexavar)
11.5.4.4.1.1. Key Trends & Growth Drivers
11.5.4.4.1.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.5.4.4.1.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.5.4.4.2. Regorafenib (Stivarga)
11.5.4.4.2.1. Key Trends & Growth Drivers
11.5.4.4.2.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.5.4.4.2.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.5.5. By End-user
11.5.5.1. Introduction
11.5.5.2. Strategic Insights
11.5.5.2.1. BPS Analysis, By End-user
11.5.5.2.2. Market Attractiveness, By End-user
11.5.5.3. Hospitals
11.5.5.3.1. Key Trends & Growth Drivers
11.5.5.3.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.5.5.3.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.5.5.4. Oncology Centers
11.5.5.4.1. Key Trends & Growth Drivers
11.5.5.4.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.5.5.4.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.5.5.5. Others
11.5.5.5.1. Key Trends & Growth Drivers
11.5.5.5.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.5.5.5.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.5.6. By Country
11.5.6.1. Introduction
11.5.6.2. Strategic Insights
11.5.6.2.1. BPS Analysis, By Country
11.5.6.2.2. Market Attractiveness, By Country
11.5.6.3. Brazil Hepatocellular Carcinoma Drugs Market
11.5.6.3.1. Key Trends & Growth Drivers
11.5.6.3.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.5.6.3.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.5.6.4. Mexico Hepatocellular Carcinoma Drugs Market
11.5.6.4.1. Key Trends & Growth Drivers
11.5.6.4.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.5.6.4.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.5.6.5. Rest of Latin America Hepatocellular Carcinoma Drugs Market
11.5.6.5.1. Key Trends & Growth Drivers
11.5.6.5.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.5.6.5.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024

11.6. Middle East & Africa Hepatocellular Carcinoma Drugs Market

11.6.1. Key Trends & Growth Drivers
11.6.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.6.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.6.4. By Drug Class
11.6.4.1. Introduction
11.6.4.2. Strategic Insights
11.6.4.2.1. BPS Analysis, By Drug Class
11.6.4.2.2. Market Attractiveness, By Drug Class
11.6.4.3. PD-1/PD-L1 Inhibitors
11.6.4.3.1. Nivolumab (Opdivo)
11.6.4.3.1.1. Key Trends & Growth Drivers
11.6.4.3.1.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.6.4.3.1.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.6.4.4. Tyrosine Kinase Inhibitors
11.6.4.4.1. Sorafenib (Nexavar)
11.6.4.4.1.1. Key Trends & Growth Drivers
11.6.4.4.1.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.6.4.4.1.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.6.4.4.2. Regorafenib (Stivarga)
11.6.4.4.2.1. Key Trends & Growth Drivers
11.6.4.4.2.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.6.4.4.2.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.6.5. By End-user
11.6.5.1. Introduction
11.6.5.2. Strategic Insights
11.6.5.2.1. BPS Analysis, By End-user
11.6.5.2.2. Market Attractiveness, By End-user
11.6.5.3. Hospitals
11.6.5.3.1. Key Trends & Growth Drivers
11.6.5.3.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.6.5.3.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.6.5.4. Oncology Centers
11.6.5.4.1. Key Trends & Growth Drivers
11.6.5.4.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.6.5.4.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.6.5.5. Others
11.6.5.5.1. Key Trends & Growth Drivers
11.6.5.5.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.6.5.5.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.6.6. By Geography
11.6.6.1. Introduction
11.6.6.2. Strategic Insights
11.6.6.2.1. BPS Analysis, By Geography
11.6.6.2.2. Market Attractiveness, By Geography
11.6.6.3. GCC Hepatocellular Carcinoma Drugs Market
11.6.6.3.1. Key Trends & Growth Drivers
11.6.6.3.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.6.6.3.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.6.6.4. North Africa Hepatocellular Carcinoma Drugs Market
11.6.6.4.1. Key Trends & Growth Drivers
11.6.6.4.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.6.6.4.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.6.6.5. South Africa Hepatocellular Carcinoma Drugs Market
11.6.6.5.1. Key Trends & Growth Drivers
11.6.6.5.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.6.6.5.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024
11.6.6.6. Rest of Middle East & Africa Hepatocellular Carcinoma Drugs Market
11.6.6.6.1. Key Trends & Growth Drivers
11.6.6.6.2. Historical Market Value 2015-2017, Market Value Forecast & Y-o-Y Growth Analysis, 2019-2024
11.6.6.6.3. Historical Market Volume 2015-2017, Market Volume Forecast & Y-o-Y Growth Analysis, 2019-2024

12. Company Profile

12.1. Market Share of Key Players in Hepatocellular Carcinoma Drugs Market
12.1.1. Novartis Pharmaceuticals
12.1.1.1. Company Overview
12.1.1.2. Product Offered
12.1.1.3. Business Strategy
12.1.1.4. Financials
12.1.1.5. SWOT Analysis
12.1.1.6. Market Share Analysis
12.1.1.7. Key Achievements & Developments
12.1.2. Bayer AG
12.1.2.1. Company Overview
12.1.2.2. Product Offered
12.1.2.3. Business Strategy
12.1.2.4. Financials
12.1.2.5. SWOT Analysis
12.1.2.6. Market Share Analysis
12.1.2.7. Key Achievements & Developments
12.1.3. Merck & Co., Inc.
12.1.3.1. Company Overview
12.1.3.2. Product Offered
12.1.3.3. Business Strategy
12.1.3.4. Financials
12.1.3.5. SWOT Analysis
12.1.3.6. Market Share Analysis
12.1.3.7. Key Achievements & Developments
12.1.4. Bristol-Myers Squibb Company
12.1.4.1. Company Overview
12.1.4.2. Product Offered
12.1.4.3. Business Strategy
12.1.4.4. Financials
12.1.4.5. SWOT Analysis
12.1.4.6. Market Share Analysis
12.1.4.7. Key Achievements & Developments
12.1.5. AbbVie Inc.
12.1.5.1. Company Overview
12.1.5.2. Product Offered
12.1.5.3. Business Strategy
12.1.5.4. Financials
12.1.5.5. SWOT Analysis
12.1.5.6. Market Share Analysis
12.1.5.7. Key Achievements & Developments
12.1.6. Johnson & Johnson
12.1.6.1. Company Overview
12.1.6.2. Product Offered
12.1.6.3. Business Strategy
12.1.6.4. Financials
12.1.6.5. SWOT Analysis
12.1.6.6. Market Share Analysis
12.1.6.7. Key Achievements & Developments
12.1.7. Celgen Corporation
12.1.7.1. Company Overview
12.1.7.2. Product Offered
12.1.7.3. Business Strategy
12.1.7.4. Financials
12.1.7.5. SWOT Analysis
12.1.7.6. Market Share Analysis
12.1.7.7. Key Achievements & Developments
12.1.8. Amgen Inc.
12.1.8.1. Company Overview
12.1.8.2. Product Offered
12.1.8.3. Business Strategy
12.1.8.4. Financials
12.1.8.5. SWOT Analysis
12.1.8.6. Market Share Analysis
12.1.8.7. Key Achievements & Developments
12.1.9. Teva Pharmaceutical Industries Ltd.
12.1.9.1. Company Overview
12.1.9.2. Product Offered
12.1.9.3. Business Strategy
12.1.9.4. Financials
12.1.9.5. SWOT Analysis
12.1.9.6. Market Share Analysis
12.1.9.7. Key Achievements & Developments
12.1.10. Pfizer Inc.
12.1.10.1. Company Overview
12.1.10.2. Product Offered
12.1.10.3. Business Strategy
12.1.10.4. Financials
12.1.10.5. SWOT Analysis
12.1.10.6. Market Share Analysis
12.1.10.7. Key Achievements & Developments
12.1.11. Takeda Pharmaceutical Co. Ltd.
12.1.11.1. Company Overview
12.1.11.2. Product Offered
12.1.11.3. Business Strategy
12.1.11.4. Financials
12.1.11.5. SWOT Analysis
12.1.11.6. Market Share Analysis
12.1.11.7. Key Achievements & Developments
12.1.12. Other Prominent Players

13. Disclaimer

Select License Type
  • Single User License $3750 USD
  • Multi-User License $4750 USD
  • Corporate User License $5750 USD

Request For Customization



Request Customization

Check Discount



Request Discount

Corporate Clients

More than 200 Clients